Abstract
Signal transduction therapy for cancer targets pathways that are over-active in cancer cells and upon which the cancer cells depend for their survival. Protein kinases are prime targets for signal transduction therapy. A major breakthrough was the introduction of the Bcr-Abl inhibitor imatinib/Gleevec into the clinic for the treatment of chronic myelogenous leukemia (CML). Nevertheless, even for this clonal disease, which has a well-characterized principle survival factor, signal transduction therapy faces two major problems: the emergence of drug-resistant clones and the persistence of a small population of cancer stem cells that re-establish the leukemia if treatment is stopped. Most cancers are far more heterogeneous than CML, so choosing the appropriate molecular targets is a major challenge. Signal transduction therapy can potentially reduce tumor mass and control cancer as a chronic disease. Complete cures will require ways of combating cancer stem cells and preventing metastasis, such as harnessing bystander effects and the immune system during treatment.
Keywords: Signal transduction therapy, kinase inhibitor, cancer
Current Signal Transduction Therapy
Title: Signal Transduction Therapy for Cancer - Whither Now?
Volume: 1 Issue: 1
Author(s): Shoshana Klein and Alexander Levitzki
Affiliation:
Keywords: Signal transduction therapy, kinase inhibitor, cancer
Abstract: Signal transduction therapy for cancer targets pathways that are over-active in cancer cells and upon which the cancer cells depend for their survival. Protein kinases are prime targets for signal transduction therapy. A major breakthrough was the introduction of the Bcr-Abl inhibitor imatinib/Gleevec into the clinic for the treatment of chronic myelogenous leukemia (CML). Nevertheless, even for this clonal disease, which has a well-characterized principle survival factor, signal transduction therapy faces two major problems: the emergence of drug-resistant clones and the persistence of a small population of cancer stem cells that re-establish the leukemia if treatment is stopped. Most cancers are far more heterogeneous than CML, so choosing the appropriate molecular targets is a major challenge. Signal transduction therapy can potentially reduce tumor mass and control cancer as a chronic disease. Complete cures will require ways of combating cancer stem cells and preventing metastasis, such as harnessing bystander effects and the immune system during treatment.
Export Options
About this article
Cite this article as:
Klein Shoshana and Levitzki Alexander, Signal Transduction Therapy for Cancer - Whither Now?, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269244
DOI https://dx.doi.org/10.2174/157436206775269244 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Disease-Responsive Drug Delivery: The Next Generation of Smart Delivery Devices
Current Drug Metabolism Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design New Perspectives in Glioblastoma: Nanoparticles-based Approaches
Current Cancer Drug Targets Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Cyclic ADP-ribose (cADPR) and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP): Novel Regulators of Ca 2+-Signaling and Cell Function
Current Molecular Medicine RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Current Neuropharmacology Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy A New Twist in Cellular Resistance to the Anticancer Drug Bleomycin-A5
Current Drug Metabolism Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Glutathione-Triggered Drug Release from Nanostructures
Current Topics in Medicinal Chemistry Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Novel Benzimidazole Derivatives: Cytotoxic and Apoptotic Properties on Lung Cancer Cell Line
Letters in Drug Design & Discovery